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Background: Expression of the Epidermal Growth Factor Receptor ligand, Amphiregulin, has been associated with
estrogen receptor positive breast cancer. As Amphiregulin is proteolytically released from the surface of breast
cancer cells, we investigated the levels of Amphiregulin in the serum of breast cancer patients and cancer-free
women to evaluate its potential utility as a breast cancer biomarker.
Findings: Serum Amphiregulin levels were quantified by ELISA from 125 cancer-free women and 114 breast cancer
patients. No significant association between serum Amphiregulin levels and breast cancer status was detected at
two cut-points evaluated.
Conclusions: Measurement of serum Amphiregulin levels lacks the necessary sensitivity and specificity for breast
cancer screening in the general population.
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Amphiregulin, a ligand of the epidermal growth factor
receptor (EGFR), was initially identified as a secreted
factor in the ERα-positive MCF7 breast cancer cell
line [1], and was shown to be estrogen-responsive [2]
in these cells. Our analyses of human breast tumors
have demonstrated a strong correlation between ERα
and Amphiregulin gene expression levels [3]. We have
demonstrated that Amphiregulin is released from the
cell surface by TACE/ADAM17 and drives EGFR pathway
activation in several breast cancer cell lines suggesting that
inhibiting the proteolytic production of EGFR ligands is a
new mechanism by which to target EGFR signaling in
cancer [3,4].
Assays such as PSA for prostate cancer and CA125 for
ovarian cancer [5] have had a pronounced effect on the
management of these diseases, but similarly useful
markers in breast cancer are lacking. We recently
reported the distribution of serum Amphiregulin in 85
cancer-free women [6]. In the current study, we have
extended our cancer-free cohort to 125 samples and* Correspondence: paraic.kenny@einstein.yu.edu
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two breast cancer cohorts: (1) women who had breast
cancer surgery at least a year prior to enrollment and
had no evidence of recurrent disease and (2) breast cancer
patients with active disease.Methods
Recruitment of human subjects
Female breast cancer patients ≥ 18 years, and receiving
routine care at Montefiore Medical Center were recruited
in two groups: (1) women who had breast cancer surgery
at least a year prior to enrollment and no evidence of
recurrent disease (n = 37) and (2) breast cancer patients
with active disease (n = 77). For patients in the latter group
with newly diagnosed disease (n = 44), Amphiregulin levels
were measured prior to surgery, after removal of the tumor
and at intervals thereafter. For the cancer-free cohort, serum
samples were acquired from anonymous donors recruited
by two commercial repositories (Innovative Research,
Novi, MI and Promeddx, Norton, MA). Donors were
non-pregnant women with no current or prior cancer
diagnosis, and no history of diabetes, hepatitis B or C, or
HIV. The study was approved by the Institutional Review
Board of the Albert Einstein College of Medicine.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Analysis of serum Amphiregulin levels in healthy females (n = 125), patients at least one year post-surgery with no evidence
of recurrent disease (Cohort 1, 31 ER + and 6 ER-) and patients with active breast cancer (Cohort 2: 43 ER + and 34 ER-). The 90th and
95th percentiles of the normal range are indicated by shading. The numbers of cases with no detectable serum Amphiregulin (<20 pg/ml) are
indicated by points below the dashed line.
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The human Amphiregulin DuoSet ELISA Development
System (R & D Systems, Minneapolis, MN) was used
to analyze Amphiregulin levels according to the manufac-
turer’s instructions. Although preliminary experiments sug-
gested that Amphiregulin is detected similarly in serum
and plasma, we tested our study hypothesis using only
serum samples in order to minimize the potential contribu-
tion of technical variation. All measurements were made
using the protocol we have previously described in detail
[6]. All serum samples were stored at -80°C until analysis,
and we found that measured Amphiregulin levels were
stable over multiple freeze-thaw cycles. Sample concentra-
tions were determined by interpolation using an eight-point
standard curve, and samples exceeding the linear range of
the assay (above approximately 1000 pg/ml) were dilutedFigure 2 Longitudinal analysis of serum Amphiregulin levels pre- and p
patients includes 30 ER + and 14 ER- patients.and analyzed again. Median Amphiregulin levels were
compared between cohorts (Kruskal-Wallis test) and
differences in the proportions of individuals with
Amphiregulin levels above and below the evaluated
cut-points (90th and 95th percentiles of the normal
range) were tested using Fisher’s Exact Test.
Results
We previously reported the distribution of serum
Amphiregulin in 85 cancer-free women, and demon-
strated that these levels do not vary with stage of the
menstrual cycle [6]. Here we have expanded this
cancer-cancer free cohort to 125 women. The threshold of
detection of the ELISA assay is 20 pg/ml and 69% of
cancer-free women did not have detectable levels above
this threshold. Women in the cancer-free cohort ranged inost-surgery and at three-monthly follow-up intervals. This group of
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correlated with age (R = 0.13). Median Amphiregulin
levels were significantly higher than found in the cancer-
free controls in the Cohort 1 ER + patients (P = 0.0068)
and in the Cohort 2 ER + patients (P = 0.019) suggesting a
shift towards Amphiregulin positivity in women with
breast cancer. To determine if this shift was sufficiently
strong to provide diagnostic utility, we evaluated two
cut-points – the 90th percentile (471 pg/ml) and the
95th percentile (1575 pg/ml) of the normal range
(Figure 1, Healthy Females).
We first evaluated the circulating Amphiregulin levels
in women who had definitive breast cancer surgery at
least one year prior to enrollment and in whom there was
no evidence of recurrent disease (Figure 1, Cohort 1).
These 37 women included 31 with prior ER-positive
breast cancer and 6 women with prior ER-negative breast
cancer. The proportion of these women with circulating
Amphiregulin above either the 90th or the 95th percentile
of the normal range was not statistically significantly
different from the cancer-free population.
We then evaluated the circulating Amphiregulin levels in
women with active breast cancer (43 with ER-positive and
34 with ER-negative breast cancer) (Figure 1, Cohort 2). In
this cohort, there was also no difference in the distribution
of serum Amphiregulin between either the ER-positive
or ER-negative patients or between this cohort and
the normal population.
We also performed longitudinal analysis of the patients
in Cohort 2 that had been newly diagnosed with breast
cancer prior to study enrollment. In these cases, serum
samples were obtained before and after surgery, and at
three monthly intervals thereafter. This subgroup included
30 patients with ER + breast cancer and 14 patients
with ER-negative breast cancer. The majority of these
patients had serum Amphiregulin levels within the
normal range and these levels were not significantly
altered following tumor removal (Figure 2). Notably,
there was one outlier case with an extremely high
baseline serum Amphiregulin level of 18,300 pg/ml.
This level was reduced by 37% after surgery and continued
to decline in follow-up analyses.Conclusions
Measurement of serum Amphiregulin levels lacks the
necessary sensitivity and specificity for breast cancer
screening in the general population.Consent
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